Cannabinoid‐mediated antinociception is enhanced in rat osteoarthritic knees

Wiley - Tập 58 Số 1 - Trang 145-153 - 2008
Niklas Schuelert1, Jason J. McDougall1
1University of Calgary, calgary, Alberta, canada

Tóm tắt

AbstractObjectiveTo determine whether local administration of the cannabinoid 1 (CB1) receptor agonist arachidonyl‐2‐chloroethylamide (ACEA) can modulate joint nociception in control rat knee joints and in experimental osteoarthritis (OA).MethodsOA was induced in male Wistar rats by intraarticular injection of 3 mg of sodium mono‐iodoacetate, with a recovery period of 14 days. Electrophysiologic recordings were made of knee joint primary afferent nerve fibers in response to normal rotation and noxious hyperrotation of the joint both before and after close intraarterial injection of different doses of ACEA.ResultsLocal application of the CB1agonist significantly reduced the firing rate of afferent nerve fibers by up to 50% in control knee joints (n = 19) and up to 62% in OA knee joints (n = 29;P< 0.01). Coadministration of the CB1receptor antagonist AM251 or the transient receptor potential vanilloid 1 (TRPV‐1) ion channel antagonist SB366791 significantly reduced the desensitizing effect of ACEA. The CB1receptor antagonist AM251 by itself had no effect in the control joint but significantly increased the firing rate of afferent nerve fibers in the OA joint.ConclusionThese findings indicate that activation of peripheral CB1receptors reduces the mechanosensitivity of afferent nerve fibers in control and OA knee joints. Blockade of either the CB1receptor or the TRPV‐1 channel significantly reduced the efficacy of ACEA, which suggests that both receptors are involved in cannabinoid‐mediated antinociception. The increased nerve activity observed following CB1receptor antagonism suggests a tonic release of endocannabinoids during OA. As such, peripheral CB1receptors may be important targets in controlling OA pain.

Từ khóa


Tài liệu tham khảo

10.1053/joca.2001.0472

Kalbhen DA, 1987, Chemical model of osteoarthritis: a pharmacological evaluation, J Rheumatol, 14

10.1016/j.pain.2006.02.015

10.1016/j.joca.2006.04.016

Schaible HG, 1983, Activation of groups III and IV sensory units in medial articular nerve by local mechanical stimulation of knee joint, J Neurophysiol, 49, 35, 10.1152/jn.1983.49.1.35

10.1016/S0165-0270(00)00310-1

10.1016/0304-3959(93)90183-P

10.1054/plef.2001.0361

Rice AS, 2001, Cannabinoids and pain, Curr Opin Investig Drugs, 2, 399

10.1016/S0301-0082(00)00031-9

10.1038/sj.bjp.0704327

10.1042/bst0260267

10.1016/S0009-3084(02)00154-8

10.1038/346561a0

10.1016/S0014-2999(00)00211-9

10.1073/pnas.96.24.14136

10.1016/S0304-3959(01)00321-9

10.1523/JNEUROSCI.15-10-06552.1995

Mackie K, 1993, Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells, Mol Pharmacol, 44, 498

Howlett AC, 1988, Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model, Mol Pharmacol, 33, 297

10.1016/S0301-0082(98)00087-2

10.1016/S0006-8993(98)01321-3

10.1016/S0306-4522(99)00220-1

10.1016/S0306-4522(00)00389-4

10.1016/j.pain.2005.09.005

10.1046/j.1460-9568.2000.00101.x

10.1038/22761

10.1016/S0165-6147(00)01459-0

10.1038/sj.bjp.0705902

Szallasi A, 1999, Vanilloid (capsaicin) receptors and mechanisms, Pharmacol Rev, 51, 159, 10.1016/S0031-6997(24)01403-0

10.1309/7AYY-VVH1-GQT5-J4R2

10.1038/39807

10.1038/sj.bjp.0705920

10.1038/35012076

10.1016/j.pain.2006.04.001

10.1016/S0304-3940(00)01211-8

10.1016/S1063-4584(03)00163-8

10.1002/art.1780400917

Hillard CJ, 1999, Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1), J Pharmacol Exp Ther, 289, 1427, 10.1016/S0022-3565(24)38289-8

10.1038/sj.ijo.0803272

10.1016/j.bmcl.2004.05.028

10.1152/jn.1985.54.5.1109

10.1152/jn.1988.60.6.2180

10.1016/S0009-3084(02)00155-X

10.1038/sj.bjp.0706984

10.1038/28393

10.1016/S0304-3959(97)00213-3

10.1016/S0304-3959(00)00474-7

10.1038/sj.bjp.0703050

10.1016/S0028-3908(03)00305-8

10.1016/j.neulet.2005.05.015

10.1201/9780203219973.ch28

10.1124/mol.105.015644

10.1016/j.neuroscience.2006.02.035

10.1038/sj.bjp.0706984

10.1016/j.neuropharm.2005.10.007

Thông tin
Thông tin xuất bản

Wiley

Tập 58 Số 1

145-153

Thông tin tác giả